1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome

3. Executive Summary

3.1. Introduction
3.2. Market Outlook
3.3. Drug Class Outlook
3.4. Distribution Outlook
3.5. Geography Outlook
3.6. Competitor Outlook

4. Market Overview

4.1. Introduction

5. Market Dynamics

5.1. Introduction
5.2. Drivers
5.2.1. Rising prevalence of cardiovascular diseases and the growing geriatric population
5.2.2. Supportive government initiatives for the development of orphan drugs
5.2.3. Clinical drugs in pipeline for pulmonary treatment
5.3. Restraints
5.3.1. Limited awareness about presence of pulmonary arterial hypertension among patients
5.3.2. High diagnosis & treatment cost of pulmonary disorders
5.4. Opportunities
5.4.1. Advance oral drugs for pulmonary arterial hypertension
5.4.2. Technology advancement such as biomaker and new gene therapy for the treatment
5.5. Challenges
5.5.1. Complicated process of clinical approval of drugs

6. Market Insights

6.1. Porters Five Forces Analysis
6.1.1. Threat of New Entrants
6.1.2. Threat of Substitutes
6.1.3. Bargaining Power of Customers
6.1.4. Bargaining Power of Suppliers
6.1.5. Industry Rivalry
6.2. Cumulative Impact of COVID-19
6.3. Client Customizations

7. Global Pulmonary Arterial Hypertension Market, By Drug Class

7.1. Introduction
7.2. Calcium Channel Blocker
7.3. Endothelin Receptor Antagonists
7.4. Phosphodiesterase 5
7.5. Prostacyclin & Prostacyclin Analog

8. Global Pulmonary Arterial Hypertension Market, By Distribution

8.1. Introduction
8.2. Hospital Pharmacy
8.3. Online Pharmacy
8.4. Retail Pharmacy

9. Americas Pulmonary Arterial Hypertension Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Pulmonary Arterial Hypertension Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. South Korea
10.10. Thailand

11. Europe, Middle East & Africa Pulmonary Arterial Hypertension Market

11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles

13.1. Arena Pharmaceuticals
13.2. Bayer AG
13.3. Bristol-Myers Squibb Company
13.4. Gilead Sciences, Inc.
13.5. GlaxoSmithKline Plc
13.6. Johnson & Johnson
13.7. Merck & Co. Inc.
13.8. Novartis International AG
13.9. Pfizer, Inc.
13.10. United Therapeutics Corporation

14. Appendix

14.1. Discussion Guide

List of Figures

FIGURE 1. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: RESEARCH EXECUTION
FIGURE 3. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2019 VS 2025 (USD MILLION)
FIGURE 4. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2019 VS 2025 (USD MILLION)
FIGURE 5. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2019 VS 2025 (USD MILLION)
FIGURE 6. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
FIGURE 7. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2017-2025 (USD MILLION)
FIGURE 8. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (%)
FIGURE 9. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 11. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: MARKET DYNAMICS
FIGURE 12. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 13. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2019 VS 2025 (%)
FIGURE 14. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2019 VS 2025 (USD MILLION)
FIGURE 15. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025
FIGURE 16. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, 2019 VS 2025 (USD MILLION)
FIGURE 17. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, 2019 VS 2025 (USD MILLION)
FIGURE 18. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE 5, 2019 VS 2025 (USD MILLION)
FIGURE 19. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN & PROSTACYCLIN ANALOG, 2019 VS 2025 (USD MILLION)
FIGURE 20. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2019 VS 2025 (%)
FIGURE 21. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2019 VS 2025 (USD MILLION)
FIGURE 22. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025
FIGURE 23. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITAL PHARMACY, 2019 VS 2025 (USD MILLION)
FIGURE 24. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ONLINE PHARMACY, 2019 VS 2025 (USD MILLION)
FIGURE 25. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY RETAIL PHARMACY, 2019 VS 2025 (USD MILLION)
FIGURE 26. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (%)
FIGURE 27. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
FIGURE 28. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 29. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
FIGURE 30. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
FIGURE 31. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
FIGURE 32. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
FIGURE 33. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
FIGURE 34. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (%)
FIGURE 35. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
FIGURE 36. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 37. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
FIGURE 38. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
FIGURE 39. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
FIGURE 40. INDONESIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
FIGURE 41. JAPAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
FIGURE 42. MALAYSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
FIGURE 43. PHILIPPINES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
FIGURE 44. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
FIGURE 45. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
FIGURE 46. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (%)
FIGURE 47. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
FIGURE 48. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 49. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
FIGURE 50. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
FIGURE 51. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
FIGURE 52. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
FIGURE 53. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
FIGURE 54. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
FIGURE 55. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
FIGURE 56. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
FIGURE 57. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
FIGURE 58. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
FIGURE 59. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
FIGURE 60. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: 360IRESEARCH FPNV POSITIONING MATRIX
FIGURE 61. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: 360IRESEARCH MARKET SHARE ANALYSIS
FIGURE 62. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, BY TYPE

List of Tables

TABLE 1. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2017-2025 (USD MILLION)
TABLE 2. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 3. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 4. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 5. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 6. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE 5, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 7. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN & PROSTACYCLIN ANALOG, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 8. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
TABLE 9. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITAL PHARMACY, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 10. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ONLINE PHARMACY, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 11. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY RETAIL PHARMACY, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 12. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 13. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 14. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
TABLE 15. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 16. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
TABLE 17. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 18. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
TABLE 19. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 20. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
TABLE 21. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 22. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
TABLE 23. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 24. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
TABLE 25. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 26. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 27. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
TABLE 28. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 29. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
TABLE 30. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 31. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
TABLE 32. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 33. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
TABLE 34. INDONESIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 35. INDONESIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
TABLE 36. JAPAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 37. JAPAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
TABLE 38. MALAYSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 39. MALAYSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
TABLE 40. PHILIPPINES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 41. PHILIPPINES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
TABLE 42. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 43. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
TABLE 44. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 45. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
TABLE 46. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
TABLE 47. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 48. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
TABLE 49. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 50. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
TABLE 51. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 52. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
TABLE 53. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 54. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
TABLE 55. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 56. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
TABLE 57. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 58. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
TABLE 59. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 60. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
TABLE 61. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 62. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
TABLE 63. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 64. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
TABLE 65. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 66. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
TABLE 67. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 68. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
TABLE 69. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2017-2025 (USD MILLION)
TABLE 70. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)
TABLE 71. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: SCORES
TABLE 72. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: BUSINESS STRATEGY
TABLE 73. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: PRODUCT SATISFACTION
TABLE 74. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: RANKING
TABLE 75. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: MERGER & ACQUISITION
TABLE 76. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 77. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 78. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: INVESTMENT & FUNDING
TABLE 79. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: AWARD, RECOGNITION, & EXPANSION

Companies Mentioned

Arena Pharmaceuticals
Bayer AG
Bristol-Myers Squibb Company
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Johnson & Johnson
Merck & Co. Inc.
Novartis International AG
Pfizer, Inc.
United Therapeutics Corporation